SCHEMBL276891

SCHEMBL276891

CCCCCC(CC)OC=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSK P43235 2/20 0.42
TSHR P16473 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ADH1B P00325 1/20 0.39
ADH1C P00326 1/20 0.39
ADH1A P07327 1/20 0.39
ADH4 P08319 1/20 0.39
ADH7 P40394 1/20 0.39
OPRM1 P35372 1/20 0.39
TRPA1 O75762 1/20 0.38
DDAH1 O94760 1/20 0.38
GAPDH P04406 1/20 0.38
MAPT P10636 1/20 0.38
TP53 P04637 1/20 0.36
PRKCA P17252 1/20 0.36
PRKCD Q05655 1/20 0.36
FDPS P14324 4/20 0.34
SMPD1 P17405 3/20 0.34
GPR84 Q9NQS5 2/20 0.33
ZDHHC7 Q9NXF8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29655326 1.00 CTSK (0.42) CTSKTSHRSMN1; SMN2ADH1BADH1C
SCHEMBL28553530 0.98 ADH1B (0.42) CTSKTSHRSMN1; SMN2ADH1BADH1C
SCHEMBL18188022 0.98 ADH1B (0.42) CTSKTSHRSMN1; SMN2ADH1BADH1C
SCHEMBL18188004 0.98 ADH1B (0.42) CTSKTSHRSMN1; SMN2ADH1BADH1C
SCHEMBL3040229 0.98 ADH1B (0.42) CTSKTSHRSMN1; SMN2ADH1BADH1C
SCHEMBL76606 0.98 ADH1B (0.42) CTSKTSHRSMN1; SMN2ADH1BADH1C
Ethane SCHEMBL28250178 0.98 CTSK (0.41) CTSKTSHRSMN1; SMN2ADH1BADH1C
SCHEMBL18187976 0.98 ADH1B (0.42) CTSKTSHRSMN1; SMN2ADH1BADH1C
SCHEMBL4138238 0.93 CTSK (0.47) CTSKTSHRSMN1; SMN2PRKCAPRKCD
SCHEMBL18188026 0.91 OPRM1 (0.42) CTSKTSHRSMN1; SMN2ADH1BADH1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250212873-A1 VOLATILE HDAC INHIBITORS FOR THERAPEUTIC AND PLANT APPLICATIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-07-03 US claimed
EP-4482306-A1 VOLATILE HDAC INHIBITORS FOR THERAPEUTIC AND PLANT APPLICATIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-01-01 EP claimed
WO-2023192424-A1 VOLATILE HD AC INHIBITORS FOR THERAPEUTIC AND PLANT APPLICATIONS CROSS-REFERENCE TO RELATED APPLICATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-10-05 WO claimed
US-9580636-B2 Secondary esters, methods of making, and uses thereof CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2017-02-28 US claimed
US-20160319178-A1 Secondary Esters, Methods of Making, and Uses Thereof CHEVRON PHILLIPS CHEMICAL COMPANY LP 2016-11-03 US claimed
WO-2016176243-A1 SECONDARY ESTERS, METHODS OF MAKING, AND USES THEREOF CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2016-11-03 WO claimed
EP-4711010-A2 PRO-PERFUME COMPOSITIONS Firmenich SA (CH) 2026-03-18 EP disclosed
US-20250263631-A1 PRO-PERFUME COMPOSITIONS FIRMENICH SA (CH) 2025-08-21 US disclosed
US-20250257284-A1 ALKYL ENOL ETHER PROPERFUME FIRMENICH SA (CH) 2025-08-14 US disclosed
US-20250212873-A1 VOLATILE HDAC INHIBITORS FOR THERAPEUTIC AND PLANT APPLICATIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-07-03 US disclosed
US-12325839-B2 Pro-perfume compositions FIRMENICH SA (CH) 2025-06-10 US disclosed
US-12291691-B2 Alkyl enol ether properfume FIRMENICH SA (CH) 2025-05-06 US disclosed
CN-111936457-B Enol ether pro-fragrances 弗门尼舍有限公司 2025-02-25 CN disclosed
CN-1798739-A 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators NISSAN CHEMICAL IND LTD (JP) 2006-07-05 CN disclosed
WO-2006062240-A1 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2006-06-15 WO disclosed
US-20060094694-A1 Heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2006-05-04 US disclosed
EP-1636192-A1 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS Nissan Chemical Industries, Ltd. (JP) 2006-03-22 EP disclosed
WO-2004108683-A1 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2004-12-16 WO disclosed
EP-0317262-A2 Transparent resin material JAPAN SYNTHETIC RUBBER CO., LTD. (JP) 1989-05-24 EP disclosed
US-4128730-A REDUCED COPPER AND NICKEL SALTS CHEMISCHE WERKE HUELS AKTIENGESELLSCHAFT (DE) 1978-12-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094694-A1 Heterocyclic compounds and thrombopoietin receptor activators NR2C2, ROR1, NR0B2 CTSK 4350/4885TSHR 47/4885SMN1; SMN2 2170/4885
US-20250257284-A1 ALKYL ENOL ETHER PROPERFUME CYP2E1, ACADM, ADH5 CTSK 2916/4885TSHR 4628/4885SMN1; SMN2 3950/4885
US-12291691-B2 Alkyl enol ether properfume CYP2E1, ACADM, ADH5 CTSK 2916/4885TSHR 4628/4885SMN1; SMN2 3950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.